Global Kinetics Corporation with researchers from the Florey Neuroscience Institute, presents the Personal KinetiGraph™ (PKG™) movement recording. The PKG™ Data Logger is a wrist worn device, that looks like a wristwatch, that automatically records movement data to assist Doctors in their diagnosis and treatment of the symptoms of movement disorders.
The Personal KinetiGraph™ (PKG™) movement recording
The PKG™ Data Logger is worn like a wrist watch and features a vibrating reminder of when patients should register that they have taken their levodopa medication as prescribed by their Doctor. It is worn continuously over 6 to 10 days in the home environment during the activities of daily living, during which time it uses an accelerometer to automatically record movement data.
This data enables a report to be created for the Neurologist showing the kinematics of symptoms of movement disorders and the timing of levodopa medication for compliance monitoring.
Having an objective record of the movement symptoms assists the Doctor’s understanding of the nature and progression of the disease. On assessment of the movement recording the Doctor may change the treatment: type, amount or timing of the medication, or recommend an advanced therapy, such as deep brain stimulation.
The Personal KinetiGraph™ - cutting edge technology being used by Doctors to help improve the quality of life for sufferers of movement disorders.
The PKG™ is cleared by the FDA for sale in the United States.
About Movement Disorders, Such as Parkinson's Disease
There is a broad range of movement disorders, with Parkinson’s Disease being the most prevalent. Globally, there are over 6 million people who have Parkinson’s Disease. 10% of people who are diagnosed with Parkinson’s Disease are younger than 50 years.
Parkinson’s Disease is a progressive disorder of the frontal lobe of the brain, the part of the brain that controls impulsive and non-impulsive movement. People with Parkinson’s have less dopamine, a chemical ‘messenger’ in the brain that sends messages to the body on how control movement.
The main motor (or movement) related symptoms of Parkinson’s Disease are are bradykinesia, rigidity, tremors, postural instability. Other non-movement symptoms may be experienced such as speech and swallowing difficulties, cognitive impairment or behavioural change and sleep disturbance.
The most common treatment for Parkinson’s disease, levodopa, aims to increase the amount of dopamine in the brain. Treatment doesn’t cure the disease, but can improve symptoms to enable people with Parkinson’s to live independently and enjoy a better quality of life. Parkinson’s disease is a challenging illness and each person may experience different symptoms with varying severity.
Other Movement Disorders include Parkinsonian Tremor, Restless Legs Syndrome, Dystonia, Huntington’s disease, Progressive Supranuclear Palsy (PSP) or Wilson’s Disease.
News and Reviews
FDA clearance received for Second Generation Personal KinetiGraph™
Global Kinetics Corporation has received notification from the US Food and Drug Administration of 510 (k) marketing clearance for its second generation technology – the PKG™-Watch.
Clearance of this technology signals a major milestone for Global Kinetics, underpinning aggressive expansion into new product and service offers to meet the needs of the Parkinson’s community worldwide.
The new technology is a core platform for the company to reach scale in the US, European and Asia Pacific clinical care markets by overcoming previous distribution and data handling constraints. It enables GKC to capitalise on our growing telehealth and clinical trial services businesses, and to build on our already substantial partnerships with global pharmaceutical and device leaders in Parkinson’s.
Developed based on extensive feedback from users of the previous-generation PKG™, the Second Generation PKG™ is smaller, more compact and includes a touch sensitive backlit screen with haptic and visual feedback, a water resistance enclosure and mobile charging and data handling capacity.
The PKG-Watch was unveiled at the World Parkinson’s Congress 2016 in Portland, Oregon, before being distributed to patients and physicians in key movement disorder clinics across the USA.
Financial Review features article on GKC's New President and CEO
A leading news source for the business, finance and investment community - The Australian Financial Review - has featured an article on the appointment of our new President and CEO, Tim Still.
The article includes an interview with Mr Still who goes on to describe his thoughts around the priorities to drive growth for the company through reimbursements in key markets.
To read the full article, please click here
Global Kinetics Corporation Announces New President and CEO
Global Kinetics Corporation is delighted to announce the appointment of US-based Timothy I. Still as its new President and CEO.
Tim joins GKC at an exciting time of rapid growth for the company, driven in part by escalating demand for its clinical product, the Personal Kinetigraph™ (PKG™). GKC’s PKG™ system is now being used to improve the management of Parkinson’s disease in 200 key movement disorder clinics across the US, Europe and the Asia Pacific.
GKC Director and Managing Director of Brandon Capital, Dr. Chris Nave said, “Tim brings a wealth of experience in healthcare and medical diagnostics to GKC. Over the past decade, Tim has successively led a number of medical technology companies, and has been responsible for building these companies into commercially viable entities. A number of them have achieved attractive exits and investor returns. He brings a unique skill-set and proven history of commercialisation which matches perfectly with GKC’s rapidly expanding sales and growth strategy.”
Mr. Still’s background includes over 26 years of experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Consistent with GKC’s international focus and increasing US presence, Tim will be based in San Francisco, California.
“I was initially drawn to GKC’s clear vision to have a measurable impact in Parkinson’s disease,” Tim said. “GKC’s product portfolio is first class and, combined with an impressive IP position and notable market demand, provides a compelling opportunity for near term commercial success,” he said. “The market in digital health for diagnostic wearables is an exciting space, and I look forward to leading the team at GKC.”